JP2007284433A5 - - Google Patents

Download PDF

Info

Publication number
JP2007284433A5
JP2007284433A5 JP2007073396A JP2007073396A JP2007284433A5 JP 2007284433 A5 JP2007284433 A5 JP 2007284433A5 JP 2007073396 A JP2007073396 A JP 2007073396A JP 2007073396 A JP2007073396 A JP 2007073396A JP 2007284433 A5 JP2007284433 A5 JP 2007284433A5
Authority
JP
Japan
Prior art keywords
irbit
composition
composition according
vivo
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007073396A
Other languages
Japanese (ja)
Other versions
JP2007284433A (en
JP5146944B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2007073396A priority Critical patent/JP5146944B2/en
Priority claimed from JP2007073396A external-priority patent/JP5146944B2/en
Publication of JP2007284433A publication Critical patent/JP2007284433A/en
Publication of JP2007284433A5 publication Critical patent/JP2007284433A5/ja
Application granted granted Critical
Publication of JP5146944B2 publication Critical patent/JP5146944B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

ＩＰ３受容体結合タンパク質（ＩＲＢＩＴ）、ＩＲＢＩＴの発現／翻訳を制御する核酸、またはＩＲＢＩＴに対する抗体を含む組成物であって、
（１）タンパク質合成、および
（２）細胞内ｐＨ、
からなる群から選択される少なくとも１つの細胞内生物学的機能の制御のための上記組成物。 A composition comprising an IP 3 receptor binding protein (IRBIT), a nucleic acid that controls the expression / translation of IRBIT, or an antibody against IRBIT,
(1) protein synthesis, and ( 2 ) intracellular pH,
The above composition for the control of at least one intracellular biological function selected from the group consisting of: 前記タンパク質合成が、切断／ポリアデニレーション特異性因子（ＣＰＳＦ）による細胞質のｍＲＮＡポリアデニレーションが関与するものである、請求項１に記載の組成物。   2. The composition of claim 1, wherein the protein synthesis involves cytoplasmic mRNA polyadenylation by a cleavage / polyadenylation specificity factor (CPSF). 前記細胞内ｐＨが、細胞内でのｐ型Ｎａ／ＨＣＯ３共トランスポーター１（ｐＮＢＣ１）が関与するものである、請求項１に記載の組成物。 The intracellular pH is, p-type Na / HCO 3 cotransporter 1 in cells (pNBC1) in which is involved, the composition of claim 1. 前記制御が、抑制または亢進である、請求項１〜３のいずれか１項に記載の組成物。 The composition according to any one of claims 1 to 3 , wherein the control is suppression or enhancement. 前記ＩＲＢＩＴが、ヒトまたはマウス由来のものである、請求項１〜４のいずれか１項に記載の組成物。 The composition according to any one of claims 1 to 4 , wherein the IRBIT is derived from a human or a mouse. 前記ＩＲＢＩＴが、配列番号１または配列番号３に示されるアミノ酸配列からなるタンパク質、あるいは該アミノ酸配列と９０％以上の同一性を有するアミノ酸配列を含みかつＩＲＢＩＴと同等の生物学的活性を有するタンパク質である、請求項１〜５のいずれか１項に記載の組成物。 The IRBIT is a protein comprising the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3, or a protein comprising an amino acid sequence having 90% or more identity with the amino acid sequence and having a biological activity equivalent to IRBIT. The composition according to any one of claims 1 to 5 . 前記組成物が、ｉｎ ｖｉｖｏ、ｉｎ ｖｉｔｒｏまたはｅｘ ｖｉｖｏのいずれかで使用される、請求項１〜６のいずれか１項に記載の組成物。 Wherein the composition, in vivo, are used either in vitro or ex vivo, a composition according to any one of claims 1-6. 前記組成物が、疾患の治療用である、請求項１〜７のいずれか１項に記載の組成物。 The composition according to any one of claims 1 to 7 , wherein the composition is used for treatment of a disease. ｉｎ ｖｉｔｒｏまたはｅｘ ｖｉｖｏでの細胞内のタンパク質合成の制御におけるＩＲＢＩＴの使用方法。   Use of IRBIT in the control of protein synthesis in cells in vitro or ex vivo. 前記ＩＲＢＩＴがＣＰＳＦに結合しＣＰＳＦの機能を制御する、請求項９に記載の方法。 The method of claim 9 , wherein the IRBIT is coupled to a CPSF to control the function of the CPSF. ｉｎ ｖｉｔｒｏまたはｅｘ ｖｉｖｏでの細胞内ｐＨの制御におけるＩＲＢＩＴの使用方法。   Use of IRBIT in controlling intracellular pH in vitro or ex vivo. 前記ＩＲＢＩＴがｐＮＢＣ１を活性化する、請求項１１に記載の方法。 The method of claim 11 , wherein the IRBIT activates pNBC1. 前記ｐＮＢＣ１の活性化が前記ＩＲＢＩＴのリン酸化を必要とする、請求項１２に記載の方法。 13. The method of claim 12 , wherein activation of the pNBC1 requires phosphorylation of the IRBIT.
JP2007073396A 2006-03-20 2007-03-20 Regulation of intracellular target molecules by IP3 receptor binding protein Expired - Fee Related JP5146944B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007073396A JP5146944B2 (en) 2006-03-20 2007-03-20 Regulation of intracellular target molecules by IP3 receptor binding protein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006077607 2006-03-20
JP2006077607 2006-03-20
JP2007073396A JP5146944B2 (en) 2006-03-20 2007-03-20 Regulation of intracellular target molecules by IP3 receptor binding protein

Publications (3)

Publication Number Publication Date
JP2007284433A JP2007284433A (en) 2007-11-01
JP2007284433A5 true JP2007284433A5 (en) 2010-05-06
JP5146944B2 JP5146944B2 (en) 2013-02-20

Family

ID=38756539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007073396A Expired - Fee Related JP5146944B2 (en) 2006-03-20 2007-03-20 Regulation of intracellular target molecules by IP3 receptor binding protein

Country Status (1)

Country Link
JP (1) JP5146944B2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516089A (en) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
JP4219648B2 (en) * 2002-10-11 2009-02-04 独立行政法人理化学研究所 Novel IP3 receptor binding protein and IP3 indicator
JP2006515747A (en) * 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases

Similar Documents

Publication Publication Date Title
EP2826791A3 (en) Humanized anti-C5aR antibodies
NO20091235L (en) Antagonistic human light-specific monoclonal antibodies
UA116614C2 (en) FACTOR ANTIBODY AND ITS APPLICATION
EA200601603A1 (en) HUMAN MIMETICAL ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
NO20083793L (en) Antibodies to amyloid-beta peptide
GEP20166454B (en) Sclerostin binding agents
CL2013002062A1 (en) Monoclonal antibody that binds to gene 3 of human lymphocyte (lag-3) activation; composition comprising said antibody; nucleic acid molecule that encodes it; expression vector and host cell comprising it: preparation method; and its use to stimulate the immune response.
NO20091387L (en) Antibodies to bone morphogenic proteins and receptors thereof, methods for their use
JP2010273685A5 (en)
JP2016527891A5 (en)
WO2010036918A3 (en) Intracellular dna receptor
JP2013503205A5 (en)
NO20090069L (en) Targeted compounds targeting binding to PDGFR-alpha and their use
AR064642A1 (en) POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
UA108066C2 (en) PROTEINS RELATING TO HUMAN CGRP RECEPTORS
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
JP2012029693A5 (en)
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
AR074397A1 (en) STABILIZED ACTIVINE IIB RECEPTING POLYEPTIDES AND USES OF THE SAME
WO2007046834A3 (en) Glp-1 agonists, compositions, methods and uses
EA200702532A1 (en) ANTIBODIES AGAINST MSR-1, COMPOSITIONS, METHODS AND APPLICATIONS
NO20064866L (en) IRTA-5 antibodies and their use
RU2019119609A (en) PEPTIDS ABLE TO REACTIVATE P53 MUTANTS
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses